Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
While sirolimus is widely used in tuberous sclerosis complex (TSC), its impact on coronavirus disease 2019 (COVID-19) vaccination remains unclear. To evaluate the safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine on the children with TSC on sirolimus, we conducted a prospective cohort study (July 1st, 2021-April 1st, 2022) in 117 children: 43 patients with sirolimus, 18 patients without sirolimus, and 56 healthy controls. Neutralizing antibody titers were measured pre-vaccination and at one and three months after the two-dose vaccination and adverse events were monitored throughout follow-up. Infection incidence was assessed via questionnaire. The primary endpoint was seroconversion rate, with secondary endpoints including neutralizing antibody titers, adverse events, and breakthrough infection incidence following China's December 2022 COVID-19 surge. Results showed lower 1-month seroconversion (75.0% [12/16] vs 98.2% [55/56], p = .001) and reduced antibody titers (median 102.1 vs 213.1 IU/mL, p = .04) in non-sirolimus group versus controls, with declining trend in 3-month responses [44.4% (8/18) vs 54.5% (30/55), median 102.1 vs 213.1 IU/mL, p > .05]. Sirolimus group demonstrated stronger humoral responses versus non-sirolimus counterparts: higher antibody titers at 1 month (median: 168.9 IU/mL vs 102.1 IU/mL, p = .029) and 3 months (median: 38.1 IU/ml vs 15.8 IU/mL, p = .011), with higher seroconversion trend [1 month: 87.5% (35/40) vs 75% (12/16) (p = .259); 3 months: 67.6% (25/37) vs 44.4% (8/18)] (p = .1). The vaccine elicited attenuated immunogenicity in non-sirolimus group whereas vaccine combined with sirolimus might provide better protection against COVID-19. COVID-19 vaccination conferred good safety with mild breakthrough infections.